Literature DB >> 12522745

Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.

Omar Y Gonzalez1, Daniel M Musher, Indira Brar, Seth Furgeson, Maha R Boktour, Edward J Septimus, Richard J Hamill, Edward A Graviss.   

Abstract

Intravesical instillation of bacille Calmette-Guérin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by generalized symptoms, with pneumonitis and hepatitis. Late-presentation disease occurs >1 year after the first BCG treatment and usually involves focal infection of the genitourinary tract (the site at which bacteria were introduced) and/or other sites that are typical for reactivation of mycobacterial disease, such as the vertebral spine or the retroperitoneal tissues. Noncaseating granulomas are found in the majority of cases, whether early or late. Most patients respond to treatment with antituberculous drugs; in early-presentation disease, when features of hypersensitivity predominate, glucocorticosteroids are sometimes added. Late localized infection often requires surgical resection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522745     DOI: 10.1086/344908

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  62 in total

1.  Severe disseminated tuberculosis after intravesical instillation of Bacillus Calmette-Guérin.

Authors:  M Toscano Rico; J Machado; O Cardoso; C Salvado; P Rodrigues; R Proença
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  Anamnestic responses of mice following Mycobacterium tuberculosis infection.

Authors:  Arati B Kamath; Samuel M Behar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

4.  Attenuated but live: a pelvic abscess caused by bacille Calmette-Guerin.

Authors:  Jerome A Leis; Daniel R Ricciuto; Wayne L Gold
Journal:  CMAJ       Date:  2011-06-13       Impact factor: 8.262

5.  A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  Colin B Josephson; Saleh Al-Azri; Daniel J Smyth; David Haase; B Lynn Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  Diagnosing the Treatment.

Authors:  Sarah A McGuffin; Robert L Trowbridge; Ann M O'Hare; Andrew P Olson
Journal:  J Hosp Med       Date:  2018-06-27       Impact factor: 2.960

7.  Multi-organ failure with atypical liver granulomas following intravesical Bacillus Calmette-Guerin instillation.

Authors:  Michail Kaklamanos; Georgia Hardavella; Rodoula Trigidou; Georgios Dionellis; Nikolaos Paissios; Nikolaos Koulouris; Constantin Goritsas
Journal:  World J Hepatol       Date:  2011-03-27

8.  Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.

Authors:  Chang-Ho Ryan Choi; Sang Oh Lee; Geoff Smith
Journal:  BMJ Case Rep       Date:  2014-05-08

9.  Direct comparison of the genotype MTBC and genomic deletion assays in terms of ability to distinguish between members of the Mycobacterium tuberculosis complex in clinical isolates and in clinical specimens.

Authors:  Akos Somoskovi; Jillian Dormandy; Jeremy Rivenburg; Maria Pedrosa; Melinda McBride; Max Salfinger
Journal:  J Clin Microbiol       Date:  2008-03-19       Impact factor: 5.948

10.  Mediastinal mass mimicking a tumor in a patient with bladder cancer after Bacillus Calmette-Guerin treatment.

Authors:  A Somoskovi; C Carlyn; J Dormandy; M Salfinger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.